Med Business World

Your source for healthcare business

Bjørn Dahl

eXeX & AdventHealth Surgery Center Innovation Tower Pioneer Use of Apple Vision Pro in Joint Replacement Surgery

eXeX, a leader in artificial intelligence enhanced surgical logistics software, has achieved a world first by successfully utilizing the Apple Vision Pro in organizing and managing a Reverse Total Shoulder Arthroplasty. This marks the first-ever use of Apple’s spatial computing…

Join Els for Autism® in Celebrating World Autism Month: Creating Opportunities for Inclusion and Acceptance of Individuals with Autism Spectrum Disorder

As we prepare to celebrate World Autism Month this April, Els for Autism invites individuals and families to join us in our mission of creating a world of limitless possibilities for individuals with autism spectrum disorder (ASD) and their families. Through our…

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety, of DA-1241, a novel G-Protein-Coupled Receptor 119…

Lupin and Birmingham City University Honour Graduates of Master’s Programme in Advancing Diabetes Care

Global pharma major Lupin Limited (Lupin) joined forces withBirmingham City University, UK (BCU) and hosted a convocation ceremony on March 9, 2024, honouringIndian healthcare professionals who completed the Master’s programme in Advancing Diabetes Care. Thisground-breaking course is tailored to empower…

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer

Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary…

IlluminOss Subsidiary ABL Medical Developing Anti-Microbial Blue Light Fiber Technology!

ABL Medical Inc. a subsidiary of IlluminOss Medical Inc. In 2018, IlluminOss Medical began offering a system in the US that used blue light delivered via a long fiber-optic catheter to harden light-curing liquid within balloon-like orthopedic implants. Now, data…

VYSIONEER Collaborates with MC Medical to Introduce the First-ever Brain Tumor Auto Contouring AI for Radiotherapy to Japan

Vysioneer, a leading innovator in Oncology AI, is proud to announce a strategic collaboration with MC Medical, a subsidiary of Mitsubishi Corporation and a wholly owned subsidiary of MC Healthcare Holdings for bringing advanced medical device around the world to Japan….

International Association for the Study of Lung Cancer (IASLC) and Lung Cancer Research Foundation (LCRF) Announce Request for Proposals

The Lung Cancer Research Foundation announced today that, in partnership with the International Association for the Study of Lung Cancer, submissions are being accepted for the $2.5 million, four-year award, titled IASLC-LCRF Team Science Research Grant on Advancing Therapies Towards Curing Oncogenic-Driven…

Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device

Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Northwestern Memorial Hospital in Chicago, Illinois (“Northwestern”)….

New Drug Application of Mabwell’s 8MW0511 for Injection Accepted by NMPA

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injection (R&D code: 8MW0511) has been accepted by the National…